Researchers around the world continue to advance the fight against SARS-CoV-2 and the development of effective antiviral therapeutics, including vaccines, peptide inhibitors, nucleoside analogues, and monoclonal antibodies. Others are developing in vitro assays for research and clinical testing.
Agilent is a manufacturer of medical devices and research instrumentation, bringing together a unique combination of complementary cell analysis platforms, optimized applications, and integrated automation solutions. Discover how Agilent cell analysis tools can provide greater insight into infectious disease research and accelerate the processing of thousands of samples
This webinar reviews the broad range of research techniques and assay formats employed to develop effective treatments and advance clinical testing. Content covers general virology applications, cellular host response studies, animal models of infection, and therapeutic development.
In this webinar, Vanderbilt University Medical Center researchers Dr. Robert Carnahan and Dr. Pavlo Gilchuk discuss their rapid discovery of highly potent neutralizing antibodies against the SARS-CoV-2 Spike protein and the validation of their activity both in vitro and in vivo.
Learn about the integration of technological advances in high-throughput, single-cell analysis to enable rapid discovery of potent human mAbs. Discover a streamlined approach to therapeutic potency verification using the xCELLigence RTCA neutralization assay.
There was no shortage of virology projects in Dr. Florian Krammer’s busy laboratory at the Icahn School of Medicine at Mount Sinai in New York City. The team was hard at work developing a universal influenza virus vaccine that could be administered two or three times in a lifetime instead of yearly. They were developing and testing monoclonal antibodies that bind to surface proteins of the influenza virus and other viruses. They were also taking a very close look at an influenza virus surface glycoprotein, called neuraminidase, to improve vaccine effectiveness.